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Supportive Care  Editorial
Touch MEdical MEdia
Recent Australian initiatives have improved the use and safety of 
opioid prescribing. The Cancer Council Australia has recently produced 
evidence-based clinical practice guidelines for the management of 
cancer pain in adults. They are intended to guide community prescribers 
in the rational management of pain with advice on the assessment and 
nonpharmacologic management of pain as well as opioid prescribing. 
This is a resource well worth exploring.1
 
It is well structured and emphasizes the need for a patient-centred 
approach to care. There are detailed sections on screening, assessment, 
and history taking. One would be surprised if it did not have a well-structured 
comprehensive component on the pharmacologic management of cancer 
pain. The emphasis on nonpharmacology and self-management, as well as 
practice improvement and quality control and opioid formulations, make 
this a valuable resource available to anyone with access to the Internet.
 
The Cancer Institute New South Wales provides another excellent Australian 
resource. Practicing oncologists will generally be well aware of eviQ,2 the 
cancer treatment online resource that provides current evidence-based, 
peer-reviewed, best practice cancer-treatment protocols and information. 
The opioid calculator included in this resource is extremely useful, not 
just for the occasional prescriber of opioids but is a valuable method of 
confirming difficult or perhaps less commonly made conversions from one 
opioid to another,3 not withstanding the continuing debate and uncertainty 
about opioid conversions.4
Morphine, named after Morpheus, the classical God of Dreams,5 has held 
a preeminent place in the pharmacologic repertoire for pain management 
in cancer pain. The understanding of pain has developed within multiple 
scientific domains. Initially it was centered on the neuroanatomy, 
physiology, and pharmacology of opioids. In early history the benefit of 
opium and derivatives of the poppy were well known but the isolation 
of morphine in 18066 and the determination of its chemical structure in 
1923 led to an explosion of knowledge.7 The poppy and its effects were 
known as far back as 3400 BCE. Hippocrates,8 in 460 BCE, dismissed the 
magic attributes of opium but acknowledged its usefulness as a narcotic, 
styptic, or antihemorrhagic agent in treating internal diseases and its useful 
for diseases of women and epidemics.
History reveals trade competitions and wars and the medicinal use in 
more recent times, includes opium tinctures, such as laudanum and 
then Brompton Cocktail, and cough and teething preparations such as 
Bonnington’s Irish Moss.9 The opioid ingredient no longer exists in the 
preparation of the same name now currently available!
We take for granted that opioids have isomers10 and binding sites.11 
Equally we assume knowledge of stereoselectivity12 and an ability 
to measure the strength of binding.13 And the population in general 
know about endogenous opioids, despite their discovery as recently 
as 1974.14 And only in the 21st century have we understood concepts 
such as excitation and also inhibition of pain signals. And we are 
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beginning to grapple with the concepts that opioids might not only 
provide analgesia, but also cause antalgesia and hyperalgesia,  i.e. they 
stimulate further pain.
Dame Cicely Saunders,16 with the modern hospice movement, pioneered 
an understanding of the available pain-relieving medications in terminal 
illness but also provided an insight into the anticipation and prevention 
rather than just the alleviation of pain.17,18 An increasing understanding 
of mechanisms other than pure nociception only add weight to her 
concept of the total nature of pain—strengthening the importance of the 
physical, social, psychologic, and spiritual components of pain and, more 
widely, of suffering.19
Opioids are available in a confusing array of preparations. Naturally cultivated 
and synthetic opioids exist. We have access to routes of administration 
that include oral, transdermal, buccal, mucosal, nasal, subcutaneous, 
intramuscular, intravenous, and inhaled. And preparations may be immediate-, 
modified-, or even sustained-release. And there are combinations or opioids 
and preparations combined with other pharmacologic agents to alleviate 
possible side effects or to prevent diversion.
And increasingly the impact and involvement of the immune system is taking 
importance, with knowledge of the involvement of microglia, mitochondria, 
and multiple inflammatory cytokines. A new area of research, the neuro-
immuno-pharmacology of opioids, is expanding.20–22
But despite these exciting advances, there is, particularly for many 
clinicians, still a sense of bewilderment. Do we really understand what 
initiates and maintains pain? In other areas of medical science there are 
developments that have lead to changing the nature of the condition 
and even preventing its occurrence. Perhaps one day we will see a 
super analgesic—the super opioid. A preparation that would relieve 
all pain, have no side effects, and be able to perhaps even prevent 
the “disease of pain.” With the rapid growth in our understanding of 
pain and its mechanisms and modifications, we have to look to neuro-
immuno-pharmacology. ■
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